0.03
—
Close of 29 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sofgen Pharma
Its shares trade under the ticker PROCF. It has been listed since 9 December 2019. In the fiscal year to 31 December 2024, it reported revenue of $373.8m and a net loss of $68.3m. At that date it held total assets of $411.7m and shareholders' equity of −$51.1m.
Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Dec 2019
- Employees
- 5,500
- Website
- procapsgroup.com ↗
- Head office
- 9 RUE DE BITBOURG, LUXEMBOURG
- Incorporated in
- N4
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Alejandro Kostia Weinstein CrenovichExecutive Chairman of the Board
- Ms. Melissa AngeliniInterim Chief Executive Officer, Director, since 2024
- Mr. Daniel BernalInterim Chief Financial Officer
- Mr. Luis Alberto Palacios AragonChief Commercial Officer
- Mr. Claudio ColombanoExecutive Director of Manufacturing Operations and Quality
- Mr. Nicolas Francisco Weinstein ManieuDirector
- Mr. Manuel ClaroIndependent Director
- Mr. Alberto CorreaIndependent Director
- Mr. Carlos IragorriIndependent Director
- Mr. Fernando MunizIndependent Director
- Mr. Carlos Romero-Camacho SilosIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates through five distinct business units.
- It develops and manufactures prescription drugs and nutritional supplements.
- Softi Gel provides contract manufacturing services to third parties.
Weaknesses
- The source text does not list specific internal weaknesses.
- Financial performance metrics are not provided in the description.
- Market share data is absent from the available facts.
Opportunities
- The firm markets branded drugs in Latin America.
- It can expand its contract manufacturing services globally.
- Growing demand for omega 3 fish oils supports Vital Care.
Threats
- The source text does not list specific external threats.
- Regulatory changes in the pharmaceutical sector are not detailed.
- Competitive pressures are not described in the provided facts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.